782 related articles for article (PubMed ID: 26743775)
1. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
[TBL] [Abstract][Full Text] [Related]
2. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
[TBL] [Abstract][Full Text] [Related]
3. Effects of Preceding Ethanol Intake on Glucose Response to Low-Dose Glucagon in Individuals With Type 1 Diabetes: A Randomized, Placebo-Controlled, Crossover Study.
Ranjan A; Nørgaard K; Tetzschner R; Steineck IIK; Clausen TR; Holst JJ; Madsbad S; Schmidt S
Diabetes Care; 2018 Apr; 41(4):797-806. PubMed ID: 29358493
[TBL] [Abstract][Full Text] [Related]
4. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
[TBL] [Abstract][Full Text] [Related]
5. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
[TBL] [Abstract][Full Text] [Related]
6. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
[TBL] [Abstract][Full Text] [Related]
8. Asymmetric changes in circulating insulin levels after an increase compared with a reduction in insulin pump basal rate in people with Type 1 diabetes.
McAuley SA; Ward GM; Horsburgh JC; Gooley JL; Jenkins AJ; MacIsaac RJ; O'Neal DN
Diabet Med; 2017 Aug; 34(8):1158-1164. PubMed ID: 28453877
[TBL] [Abstract][Full Text] [Related]
9. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
[TBL] [Abstract][Full Text] [Related]
10. Algorithm that delivers an individualized rapid-acting insulin dose after morning resistance exercise counters post-exercise hyperglycaemia in people with Type 1 diabetes.
Turner D; Luzio S; Gray BJ; Bain SC; Hanley S; Richards A; Rhydderch DC; Martin R; Campbell MD; Kilduff LP; West DJ; Bracken RM
Diabet Med; 2016 Apr; 33(4):506-10. PubMed ID: 26220149
[TBL] [Abstract][Full Text] [Related]
11. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
Toft-Nielsen MB; Madsbad S; Holst JJ
Diabetes Care; 1999 Jul; 22(7):1137-43. PubMed ID: 10388979
[TBL] [Abstract][Full Text] [Related]
12. Low-Carbohydrate Diet Impairs the Effect of Glucagon in the Treatment of Insulin-Induced Mild Hypoglycemia: A Randomized Crossover Study.
Ranjan A; Schmidt S; Damm-Frydenberg C; Steineck I; Clausen TR; Holst JJ; Madsbad S; Nørgaard K
Diabetes Care; 2017 Jan; 40(1):132-135. PubMed ID: 27797928
[TBL] [Abstract][Full Text] [Related]
13. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
[TBL] [Abstract][Full Text] [Related]
14. Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.
Heise T; Bain SC; Bracken RM; Zijlstra E; Nosek L; Stender-Petersen K; Rabøl R; Rowe E; Haahr HL
Diabetes Obes Metab; 2016 Feb; 18(2):196-9. PubMed ID: 26450456
[TBL] [Abstract][Full Text] [Related]
15. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial.
Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R
Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323
[TBL] [Abstract][Full Text] [Related]
16. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
[TBL] [Abstract][Full Text] [Related]
17. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
[TBL] [Abstract][Full Text] [Related]
18. Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Krentz AJ; Morrow L; Petersson M; Norjavaara E; Hompesch M
Diabetes Obes Metab; 2014 Nov; 16(11):1096-101. PubMed ID: 24909093
[TBL] [Abstract][Full Text] [Related]
19. Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.
Agesen RM; Kristensen PL; Beck-Nielsen H; Nørgaard K; Perrild H; Jensen T; Parving HH; Thorsteinsson B; Tarnow L; Pedersen-Bjergaard U
Diabetes Technol Ther; 2018 Mar; 20(3):247-256. PubMed ID: 29565719
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels.
Blauw H; Wendl I; DeVries JH; Heise T; Jax T;
Diabetes Obes Metab; 2016 Jan; 18(1):34-9. PubMed ID: 26343550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]